WASHINGTON — It’s going to be a bumpy 2022 for the Food and Drug Administration.
Even as the agency waits for the Senate to confirm a permanent leader, it’s gearing up for a battle with lawmakers over the future of the user-fee program that provides nearly half its revenue. On top of that, it is still struggling to keep up with responding to the Covid-19 pandemic.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
